-
2
-
-
33645763970
-
2004 WHO classification of the renal tumors of the adults
-
Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z,. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006; 49: 798-805.
-
(2006)
Eur Urol.
, vol.49
, pp. 798-805
-
-
Lopez-Beltran, A.1
Scarpelli, M.2
Montironi, R.3
Kirkali, Z.4
-
3
-
-
51049084870
-
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors
-
et al.
-
Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008; 14: 4726-4734.
-
(2008)
Clin Cancer Res.
, vol.14
, pp. 4726-4734
-
-
Nickerson, M.L.1
Jaeger, E.2
Shi, Y.3
-
4
-
-
80052263465
-
ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of metastatic disease
-
et al.
-
Patard JJ, Pignot G, Escudier B, et al. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011; 60: 684-690.
-
(2011)
Eur Urol.
, vol.60
, pp. 684-690
-
-
Patard, J.J.1
Pignot, G.2
Escudier, B.3
-
5
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
et al.
-
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
-
(2007)
N Engl J Med.
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
6
-
-
64049084146
-
Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis
-
et al.
-
Escudier BJ, Ravaud A, Negrier S, et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. ASCO Meeting Abstracts. 2008; 26: 5025.
-
(2008)
ASCO Meeting Abstracts.
, vol.26
, pp. 5025
-
-
Escudier, B.J.1
Ravaud, A.2
Negrier, S.3
-
7
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
et al.
-
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281.
-
(2007)
N Engl J Med.
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
8
-
-
77956227464
-
Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors
-
et al.
-
Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116: 4256-4265.
-
(2010)
Cancer.
, vol.116
, pp. 4256-4265
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
9
-
-
68949145218
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
-
et al.
-
Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 3584-3590.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
10
-
-
82755183572
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial
-
et al.
-
Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378: 1931-1939.
-
(2011)
Lancet.
, vol.378
, pp. 1931-1939
-
-
Rini, B.I.1
Escudier, B.2
Tomczak, P.3
-
11
-
-
73349084973
-
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study
-
et al.
-
Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27: 5794-5799.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 5794-5799
-
-
Heng, D.Y.1
Xie, W.2
Regan, M.M.3
-
12
-
-
84873080330
-
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study
-
et al.
-
Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013; 14: 141-148.
-
(2013)
Lancet Oncol.
, vol.14
, pp. 141-148
-
-
Heng, D.Y.1
Xie, W.2
Regan, M.M.3
-
13
-
-
3242770671
-
Overall C as a measure of discrimination in survival analysis: Model specific population value and confidence interval estimation
-
Pencina MJ, D'Agostino RB,. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004; 23: 2109-2123.
-
(2004)
Stat Med.
, vol.23
, pp. 2109-2123
-
-
Pencina, M.J.1
D'Agostino, R.B.2
-
14
-
-
77952318310
-
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206
-
et al.
-
Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010; 28: 2137-2143.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 2137-2143
-
-
Rini, B.I.1
Halabi, S.2
Rosenberg, J.E.3
-
15
-
-
18844386435
-
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
-
Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB,. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005; 28: 488-495.
-
(2005)
J Immunother.
, vol.28
, pp. 488-495
-
-
Upton, M.P.1
Parker, R.A.2
Youmans, A.3
McDermott, D.F.4
Atkins, M.B.5
-
16
-
-
0036569472
-
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology
-
Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V,. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol. 2002; 20: 2376-2381.
-
(2002)
J Clin Oncol.
, vol.20
, pp. 2376-2381
-
-
Motzer, R.J.1
Bacik, J.2
Mariani, T.3
Russo, P.4
Mazumdar, M.5
Reuter, V.6
-
17
-
-
37849001813
-
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
-
et al.
-
Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008; 26: 127-131.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 127-131
-
-
Choueiri, T.K.1
Plantade, A.2
Elson, P.3
-
18
-
-
67651201656
-
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial
-
et al.
-
Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009; 10: 757-763.
-
(2009)
Lancet Oncol.
, vol.10
, pp. 757-763
-
-
Gore, M.E.1
Szczylik, C.2
Porta, C.3
-
19
-
-
84864922628
-
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
-
et al.
-
Lee JL, Ahn JH, Lim HY, et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol. 2012; 23: 2108-2114.
-
(2012)
Ann Oncol.
, vol.23
, pp. 2108-2114
-
-
Lee, J.L.1
Ahn, J.H.2
Lim, H.Y.3
-
20
-
-
84868532639
-
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma
-
et al.
-
Tannir NM, Plimack E, Ng C, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012; 62: 1013-1019.
-
(2012)
Eur Urol.
, vol.62
, pp. 1013-1019
-
-
Tannir, N.M.1
Plimack, E.2
Ng, C.3
-
21
-
-
84875614863
-
Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma
-
et al.
-
Koh Y, Lim HY, Ahn JH, et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol. 2013; 24: 1026-1031.
-
(2013)
Ann Oncol.
, vol.24
, pp. 1026-1031
-
-
Koh, Y.1
Lim, H.Y.2
Ahn, J.H.3
-
22
-
-
67651056360
-
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies
-
et al.
-
Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009; 26: 202-209.
-
(2009)
Med Oncol.
, vol.26
, pp. 202-209
-
-
Dutcher, J.P.1
De Souza, P.2
McDermott, D.3
-
23
-
-
34547108341
-
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
-
et al.
-
Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007; 110: 543-550.
-
(2007)
Cancer.
, vol.110
, pp. 543-550
-
-
Choueiri, T.K.1
Garcia, J.A.2
Elson, P.3
-
24
-
-
80051699497
-
Prognostic model for survival in patients with metastatic renal cell carcinoma: Results from the international kidney cancer working group
-
et al.
-
Manola J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res. 2011; 17: 5443-5450.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 5443-5450
-
-
Manola, J.1
Royston, P.2
Elson, P.3
-
25
-
-
54049095545
-
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
-
et al.
-
Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008; 113: 1552-1558.
-
(2008)
Cancer.
, vol.113
, pp. 1552-1558
-
-
Motzer, R.J.1
Bukowski, R.M.2
Figlin, R.A.3
-
26
-
-
33750293584
-
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling
-
et al.
-
Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A. 2006; 103: 15552-15557.
-
(2006)
Proc Natl Acad Sci U S A.
, vol.103
, pp. 15552-15557
-
-
Baba, M.1
Hong, S.B.2
Sharma, N.3
-
27
-
-
79960378039
-
New insights into the biology of renal cell carcinoma
-
Li L, Kaelin WG Jr,. New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am. 2011; 25: 667-686.
-
(2011)
Hematol Oncol Clin North Am.
, vol.25
, pp. 667-686
-
-
Li, L.1
Kaelin, Jr.W.G.2
-
28
-
-
84872548337
-
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
-
et al.
-
Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013; 31: 181-186.
-
(2013)
J Clin Oncol.
, vol.31
, pp. 181-186
-
-
Choueiri, T.K.1
Vaishampayan, U.2
Rosenberg, J.E.3
-
29
-
-
0036138580
-
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
-
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M,. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 289-296.
-
(2002)
J Clin Oncol.
, vol.20
, pp. 289-296
-
-
Motzer, R.J.1
Bacik, J.2
Murphy, B.A.3
Russo, P.4
Mazumdar, M.5
|